First Citizens Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $580K | Buy |
1,168
+76
| +7% | +$33.7K | 0.01% | 439 |
|
|
2026
Q1 | $488K | Buy |
1,092
+182
| +20% | +$84.9K | 0.01% | 441 |
|
|
2025
Q4 | $413K | Sell |
910
-730
| -45% | -$315K | 0.01% | 474 |
|
|
2025
Q3 | $642K | Buy |
1,640
+37
| +2% | +$15.5K | 0.01% | 384 |
|
|
2025
Q2 | $714K | Sell |
1,603
-2,594
| -62% | -$1.2M | 0.01% | 343 |
|
|
2025
Q1 | $2.03M | Sell |
4,197
-639
| -13% | -$298K | 0.05% | 188 |
|
|
2024
Q4 | $1.95M | Sell |
4,836
-21,153
| -81% | -$9.81M | 0.04% | 185 |
|
|
2024
Q3 | $12.1M | Sell |
25,989
-1,410
| -5% | -$677K | 0.27% | 56 |
|
|
2024
Q2 | $12.8M | Sell |
27,399
-411
| -1% | -$178K | 0.24% | 53 |
|
|
2024
Q1 | $11.6M | Buy |
27,810
+6,414
| +30% | +$2.71M | 0.22% | 55 |
|
|
2023
Q4 | $8.71M | Sell |
21,396
-647
| -3% | -$239K | 0.16% | 59 |
|
|
2023
Q3 | $7.67M | Sell |
22,043
-3,761
| -15% | -$1.32M | 0.15% | 58 |
|
|
2023
Q2 | $9.08M | Buy |
25,804
+5,908
| +30% | +$1.99M | 0.17% | 57 |
|
|
2023
Q1 | $6.27M | Buy |
19,896
+8,602
| +76% | +$2.58M | 0.13% | 67 |
|
|
2022
Q4 | $3.26M | Sell |
11,294
-80
| -0.7% | -$24.4K | 0.1% | 82 |
|
|
2022
Q3 | $3.29M | Sell |
11,374
-2,619
| -19% | -$754K | 0.11% | 86 |
|
|
2022
Q2 | $3.94M | Buy |
13,993
+543
| +4% | +$145K | 0.14% | 75 |
|
|
2022
Q1 | $3.51M | Buy |
13,450
+483
| +4% | +$115K | 0.14% | 94 |
|
|
2021
Q4 | $2.85M | Buy |
12,967
+164
| +1% | +$31.9K | 0.11% | 107 |
|
|
2021
Q3 | $2.32M | Sell |
12,803
-1,165
| -8% | -$227K | 0.11% | 110 |
|
|
2021
Q2 | $2.82M | Sell |
13,968
-751
| -5% | -$157K | 0.13% | 99 |
|
|
2021
Q1 | $3.16M | Buy |
14,719
+269
| +2% | +$59.1K | 0.15% | 95 |
|
|
2020
Q4 | $3.42M | Sell |
14,450
-484
| -3% | -$111K | 0.17% | 86 |
|
|
2020
Q3 | $4.06M | Buy |
14,934
+1,598
| +12% | +$441K | 0.29% | 65 |
|
|
2020
Q2 | $3.87M | Buy |
13,336
+4,706
| +55% | +$1.28M | 0.32% | 75 |
|
|
2020
Q1 | $2.05M | Buy |
8,630
+5,518
| +177% | +$1.27M | 0.25% | 93 |
|
|
2019
Q4 | $681K | Buy |
+3,112
| New | +$630K | 0.07% | 196 |
|
|
2019
Q2 | – | Sell |
-5,442
| Closed | -$1M | – | 441 |
|
|
2019
Q1 | $1M | Buy |
5,442
+570
| +12% | +$105K | 0.11% | 180 |
|
|
2018
Q4 | $807K | Buy |
+4,872
| New | +$844K | 0.1% | 192 |
|
|
2018
Q2 | – | Sell |
-4,798
| Closed | -$782K | – | 458 |
|
|
2018
Q1 | $782K | Buy |
+4,798
| New | +$784K | 0.11% | 196 |
|
|
2017
Q4 | – | Sell |
-2,720
| Closed | -$414K | – | 432 |
|
|
2017
Q3 | $414K | Buy |
+2,720
| New | +$409K | 0.05% | 245 |
|
|
2013
Q4 | – | Sell |
-21,926
| Closed | -$1.66M | – | 791 |
|
|
2013
Q3 | $1.66M | Buy |
21,926
+2,456
| +13% | +$195K | 0.06% | 277 |
|
|
2013
Q2 | $1.56M | Buy |
+19,470
| New | +$1.43M | 0.06% | 278 |
|
Other funds holding VRTX
First Citizens Bank & Trust's VRTX Position: Q2 2026 in Review
First Citizens Bank & Trust increased its Vertex Pharmaceuticals (VRTX) stake by 7% in Q2 2026, buying an estimated $33.7K and bringing the position to 1,168 shares worth $580K. The position accounts for 0.01% of the portfolio, ranked #439.
First Citizens Bank & Trust first reported a position in VRTX in Q2 2013 and has held it in 33 quarters since. The position peaked at $12.8M in Q2 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- First Citizens Bank & Trust held 1,168 shares of Vertex Pharmaceuticals worth $580K as of Q2 2026.
- First Citizens Bank & Trust bought 76 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.7K.
- Vertex Pharmaceuticals made up 0.01% of First Citizens Bank & Trust's portfolio in Q2 2026, its #439 holding.
- First Citizens Bank & Trust first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
- First Citizens Bank & Trust's Vertex Pharmaceuticals position peaked at $12.8M in Q2 2024.
- 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on First Citizens Bank & Trust's 13F filing for Q2 2026, filed 13 Jul 2026.